scanance.
Sign inGet Premium
BW

BrainsWay Ltd.

BWAYHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$52.2M
+27.3% YoY
Net Income
$7.6M
+161.3% YoY
EBITDA
$11.5M
+69.8% YoY
Free Cash Flow
$3.0M

Scan Results

Daily timeframe
DateIndicatorDetails
Loading...
About BrainsWay Ltd.

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. At a $637.0M market cap, BrainsWay Ltd. ranks as a small-cap company within healthcare. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

Key stats
Market Cap$637.0M
P/E (TTM)72.23
Fwd P/E34.05
EPS$0.22
Beta0.22
52W Change+211.0%
ROE12.6%
Analysis

The balance sheet looks solid with $58.6M in cash comfortably exceeding the $6.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $3.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 12.6% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.3% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $27.2M (2022) to $52.2M (2025), reflecting a 92% increase over the period.

The relatively low beta of 0.22 suggests BWAY is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, BWAY has financial flexibility that may help navigate uncertain periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing BWAY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms